The estimated Net Worth of Marijn E Dekkers is at least $4.21 Milion dollars as of 11 January 2021. Marijn Dekkers owns over 16,661 units of Quanterix Corp stock worth over $27,399 and over the last 21 years he sold QTRX stock worth over $4,046,352. In addition, he makes $136,085 as Independent Director at Quanterix Corp.
Marijn has made over 9 trades of the Quanterix Corp stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 16,661 units of QTRX stock worth $925,019 on 11 January 2021.
The largest trade he's ever made was selling 89,759 units of Quanterix Corp stock on 20 August 2019 worth over $1,223,415. On average, Marijn trades about 3,318 units every 74 days since 2003. As of 11 January 2021 he still owns at least 2,270 units of Quanterix Corp stock.
You can see the complete history of Marijn Dekkers stock trades at the bottom of the page.
Dr. Marijn E. Dekkers Ph.D. serves as Independent Director of the Company. He is the founder and Chairman of Novalis LifeSciences LLC, an investment and advisory firm for the life science industry. From 2016 to 2019, Dr. Dekkers was Chairman of the board of directors of Unilever. From 2010 to 2016, Dr. Dekkers was Chief Executive Officer of Bayer AG in Leverkusen, Germany. From 2000 to 2002, he was the Chief Operating Officer at Thermo Electron Corporation (later renamed Thermo Fisher Scientific Inc.). In 2002, he became Thermo Fisher's President and Chief Executive Officer, where he served until 2009. Dr. Dekkers began his career in 1985 as a research scientist at General Electric Company. He currently serves as a director of the following private companies: Cerevel Therapeutics since December 2018, Ginkgo Bioworks since April 2019, and BioQ Pharma since January 2020. He holds a degree in chemistry from Radboud University in Nijmegen, the Netherlands, and a Ph.D. in chemical engineering from the University of Eindhoven. Dr. Dekkers's qualifications for service as a member of our board of directors include his substantial experience leading commercial stage healthcare companies and his significant corporate governance experience.
As the Independent Director of Quanterix Corp, the total compensation of Marijn Dekkers at Quanterix Corp is $136,085. There are 11 executives at Quanterix Corp getting paid more, with E. Kevin Hrusovsky having the highest compensation of $3,631,000.
Marijn Dekkers is 62, he's been the Independent Director of Quanterix Corp since 2017. There are 4 older and 16 younger executives at Quanterix Corp. The oldest executive at Quanterix Corp is Dr. David R. Walt Ph.D., 68, who is the Co-Founder, Chairman of Scientific Advisory Board & Independent Director.
Marijn's mailing address filed with the SEC is C/O QUANTERIX CORPORATION,, 900 MIDDLESEX TURNPIKE, BILLERICA, MA, 01821.
Over the last 7 years, insiders at Quanterix Corp have traded over $25,118,881 worth of Quanterix Corp stock and bought 1,481,095 units worth $18,701,541 . The most active insiders traders include David R Walt, Paul M Meister oraz Keith Crandell. On average, Quanterix Corp executives and independent directors trade stock every 7 days with the average trade being worth of $100,483. The most recent stock trade was executed by Masoud Toloue on 13 August 2024, trading 19,000 units of QTRX stock currently worth $207,100.
quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).
Quanterix Corp executives and other stock owners filed with the SEC include: